Patients aged 3-25 years with NF1-related PNs and imaging evidence of tumor progression were randomized in a double-blinded fashion to receive tipifarnib ( 200 mg/m ( 2 ) orally every 12 h ) or placebo ( phase A ) and crossed over to the opposite treatment arm at the time of tumor progression ( phase B ) .